Physician

Helena G Altick, M.D.

According to 2025 Medicare claims, Helena Altick, M.D. (NPI: 1487102109) practices family practice in the Monroe, LA market, with the plurality of this provider's patient population coming from Ouachita, LA. This provider's primary affiliated billing organization is JAMES A. ALTICK ,JR. M.D. A PROFESSIONAL MEDICAL CORPORATION (NPI: 1639641673) and primary practice location at 71201-5139.

Altick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,680 traditional Medicare patients, billed 20,554 HCPCS/CPT codes, and received $555,843 in Medicare payments. The top billing code was 17004 (Destruction of precancer skin growth, 15 or more growths). Part D data shows 2,496 prescription claims across 837 beneficiaries totaling $1,410,898 in drug costs, led by Dupixent Pen (Dupilumab). Open Payments data shows 7 records totaling $353. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $392 to $1,410,898. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$283K$566K2021 Medicare payment: $384,647 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $484,936 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $566,271 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $555,843 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
20211,48813,497$384,647
20221,68217,213$484,936
20231,70618,047$566,271
20241,68020,554$555,843

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$705K$1.4M2020 Drug cost: $392 (USD; Tot_Drug_Cst)2021 Drug cost: $503,295 (USD; Tot_Drug_Cst)2022 Drug cost: $1,191,634 (USD; Tot_Drug_Cst)2023 Drug cost: $1,349,219 (USD; Tot_Drug_Cst)2024 Drug cost: $1,410,898 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
20201219$392
20215631,348$503,295
20228432,437$1,191,634
20238412,426$1,349,219
20248372,496$1,410,898

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17004Destruction of precancer skin growth, 15 or more growths268405$91
11102Biopsy of related skin growth, first growth547726$59
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,3692,364$52
17000Destruction of precancer skin growth, 1 growth1,1731,949$33
17003Destruction of precancer skin growth, 2-14 growths1,01510,653$4

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Dupixent PenDupilumab1323,892$546,547
Skyrizi PenRisankizumab-Rzaa141,064$295,934
Humira(Cf) PenAdalimumab18504$123,420
Clobetasol PropionateClobetasol Propionate1283,602$5,761
KetoconazoleKetoconazole3568,490$5,334

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.7$353Janssen Biotech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Helena G. Altick, M.D.?

Tedicare shows public-source Medicare data for Helena G. Altick, M.D. (NPI 1487102109), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Helena G. Altick, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Helena G. Altick, M.D.?

Helena G. Altick, M.D. is linked to JAMES A. ALTICK ,JR. M.D. A PROFESSIONAL MEDICAL CORPORATION (billing NPI 1639641673) in the available physician profile data.

Does Helena G. Altick, M.D. have Open Payments data?

Helena G. Altick, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.